What is the specific role of the cleavable linker in the anti-Rat IgG(Fc)-C-MMAF ADC?

The cleavable linker in the anti-Rat IgG(Fc)-C-MMAF ADC is designed to be stable in the bloodstream, reducing the premature release of the cytotoxic agent MMAF. Once the ADC is internalized by target cells via Fc receptor-mediated endocytosis, the linker is cleaved within the cell, releasing MMAF to exert its cytotoxic effects by disrupting microtubule dynamics.

What advantages does targeting the Fc region of rat IgG offer in this ADC?

Targeting the Fc region of rat IgG allows the ADC to specifically bind to cells that express receptors for this region, enhancing the specificity of the ADC for certain immune cells or cancer cells that have been engineered to express this receptor, thus minimizing the impact on non-target cells.

How does glycosylation of the Fc fragment influence the activity of the anti-Rat IgG(Fc)-C-MMAF ADC?

The glycosylation of the Fc fragment is crucial for its binding affinity to Fc receptors on target cells. This glycosylation enhances the ADC's ability to be internalized by the target cells, which is essential for the delivery and subsequent release of the cytotoxic agent MMAF.

What types of cancer cells could potentially be targeted by the anti-Rat IgG(Fc)-C-MMAF ADC?

The ADC is particularly suited for targeting any cancer cells that are engineered to express rat IgG Fc receptors or naturally express related receptors that can bind the Fc region of rat IgG. This includes certain hematologic cancers and potentially some solid tumors.

What considerations should be taken into account when designing an experiment using the anti-Rat IgG(Fc)-C-MMAF ADC in a laboratory setting?

When designing experiments with the anti-Rat IgG(Fc)-C-MMAF ADC, researchers should ensure the target cells express rat IgG Fc receptors to enable effective binding and internalization of the ADC. It's also crucial to determine the optimal dosage and incubation times to achieve desired effects while minimizing potential cytotoxicity. Including controls that lack the receptor can help in assessing the specificity and efficacy of the ADC under various experimental conditions.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-Rat IgG(Fc)-C-MMAF ADC

anti-Rat IgG(Fc)-C-MMAF ADC (CAT#: ADC-AA-040)

This ADC product is comprised of an anti-rat IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAF. The antibody portion is a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
anti-rat IgG Fc specific polyclonal IgG antibody

Species Reactivity
Rat

Name
Cleavable linkers

Description
Cleavable linkers rely on the physiological stimuli, which mainly include chemically cleavable linkers and enzymatically cleavable linkers. Chemically cleavable linkers including acid-labile linkers and disulfide linkers. For acid-labile linkers, intracellular release of payloads relies on the different pH between endosomes/lysosomes and blood. The release of disulﬁde-linked drugs is controlled by the factors in intracellular environment. Enzymatically cleavable linkers, peptide linkers and β-glucuronide linkers, are sensitive to enzymes located in cytoplasm.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-040. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Highly Effective ADC

The anti-Rat IgG(Fc)-C-MMAF ADC has significantly enhanced our cell death studies with its specific targeting and effective cytotoxicity.

Excellent

Reliable and Specific

This ADC offers precise tubulin binding and microtubule disruption, making it indispensable for our cytotoxic research on rat antibodies.

Excellent

Superior in Performance

The use of the anti-Rat IgG(Fc)-C-MMAF ADC in our lab has yielded consistent results with no background toxicity, ideal for pre-screening studies

Excellent

Essential Research Tool

The specificity of the Fc targeting combined with MMAF's potent action provides a robust platform for studying immune cell effects.

Excellent

Top-Notch ADC

The cleavable linker design enhances delivery precision, making the anti-Rat IgG(Fc)-C-MMAF ADC a key player in our immunotherapy research.

Q: 1: What is the specific role of the cleavable linker in the anti-Rat IgG(Fc)-C-MMAF ADC?
A: The cleavable linker in the anti-Rat IgG(Fc)-C-MMAF ADC is designed to be stable in the bloodstream, reducing the premature release of the cytotoxic agent MMAF. Once the ADC is internalized by target cells via Fc receptor-mediated endocytosis, the linker is cleaved within the cell, releasing MMAF to exert its cytotoxic effects by disrupting microtubule dynamics.
Q: 2: What advantages does targeting the Fc region of rat IgG offer in this ADC?
A: Targeting the Fc region of rat IgG allows the ADC to specifically bind to cells that express receptors for this region, enhancing the specificity of the ADC for certain immune cells or cancer cells that have been engineered to express this receptor, thus minimizing the impact on non-target cells.
Q: 3: How does glycosylation of the Fc fragment influence the activity of the anti-Rat IgG(Fc)-C-MMAF ADC?
A: The glycosylation of the Fc fragment is crucial for its binding affinity to Fc receptors on target cells. This glycosylation enhances the ADC's ability to be internalized by the target cells, which is essential for the delivery and subsequent release of the cytotoxic agent MMAF.
Q: 4: What types of cancer cells could potentially be targeted by the anti-Rat IgG(Fc)-C-MMAF ADC?
A: The ADC is particularly suited for targeting any cancer cells that are engineered to express rat IgG Fc receptors or naturally express related receptors that can bind the Fc region of rat IgG. This includes certain hematologic cancers and potentially some solid tumors.
Q: 5: What considerations should be taken into account when designing an experiment using the anti-Rat IgG(Fc)-C-MMAF ADC in a laboratory setting?
A: When designing experiments with the anti-Rat IgG(Fc)-C-MMAF ADC, researchers should ensure the target cells express rat IgG Fc receptors to enable effective binding and internalization of the ADC. It's also crucial to determine the optimal dosage and incubation times to achieve desired effects while minimizing potential cytotoxicity. Including controls that lack the receptor can help in assessing the specificity and efficacy of the ADC under various experimental conditions.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-049	Protein G-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-010	anti-HIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
WJY-0423-LS107	Protein A-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-064	Anti-HIgG(Fab)-C-MMAF ADC	Cleavable linkers	MMAF
ADC-AA-066	Anti-Rat IgG(H+L)-C-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)

CAT#	Product Name	Linker	Payload
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-491	Anti-TNFRSF17-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-537	Anti-TPBG-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.